Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | METAP2 | P50579 | 3/20 | 0.57 |
| ▸ | CCR9 | P51686 | 1/20 | 0.56 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.51 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.51 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TCF4 | P15884 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27062 | 0.91 | LMNA (0.79) | BDKRB1LMNAHTTMAPTKMT2A | |
| SCHEMBL12220857 | 0.87 | LMNA (0.81) | BDKRB1LMNAHTTMAPTKMT2A | |
| SCHEMBL13484207 | 0.86 | LMNA (0.72) | BDKRB1LMNAHTTMAPTKMT2A | |
| SCHEMBL28841475 | 0.81 | BDKRB1 (0.59) | BDKRB1LMNAHTTMAPTKMT2A | |
| SCHEMBL29878721 | 0.81 | BDKRB1 (0.59) | BDKRB1LMNAHTTMAPTKMT2A | |
| SCHEMBL2534878 | 0.81 | LMNA (0.86) | BDKRB1LMNAHTTMAPTKMT2A | |
| SCHEMBL13077399 | 0.80 | LMNA (0.66) | BDKRB1LMNAHTTMAPTKMT2A | |
| SCHEMBL10251870 | 0.80 | CCR9 (0.70) | LMNAHTTMAPTKMT2ATP53 | |
| SCHEMBL13138224 | 0.79 | LMNA (0.65) | BDKRB1LMNAHTTMAPTKMT2A | |
| SCHEMBL10248298 | 0.79 | LMNA (0.56) | LMNAHTTMAPTKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280074-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7659272-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280074-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | BDKRB1 81/4885LMNA 3548/4885HTT 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.